NAPLEX (North American Pharmacist Licensure Examination) Practice Exam

Disable ads (and more) with a membership for a one time $2.99 payment

Prepare to ace the NAPLEX. Utilize flashcards and multiple choice questions with hints and explanations. Equip yourself thoroughly for the exam!

Each practice test/flash card set has 50 randomly selected questions from a bank of over 500. You'll get a new set of questions each time!

Practice this question and more.

Why is Lasmiditan (Reyvow) NOT contraindicated in patients with CVD?

It does not cause vasoconstriction
It is a non-selective serotonin receptor antagonist
It has no interaction with CYP3A4 inhibitors
It is not metabolized by the liver

The correct answer is: It does not cause vasoconstriction

Lasmiditan (Reyvow) is not contraindicated in patients with cardiovascular disease (CVD) because it does not cause vasoconstriction. This is a crucial point because vasoconstriction can potentially worsen cardiovascular conditions by increasing the workload on the heart and narrowing blood vessels, leading to increased blood pressure. Since Lasmiditan does not cause vasoconstriction, it is considered safer for patients with pre-existing cardiovascular conditions. Options B, C, and D are incorrect: - Option B stating that Lasmiditan is a non-selective serotonin receptor antagonist is not a reason why it is not contraindicated in CVD. In fact, the mechanism of action of Lasmiditan, which involves selective agonism of the 5-HT1F receptor, is unrelated to its safety in CVD. - Option C mentioning no interaction with CYP3A4 inhibitors and Option D stating that it is not metabolized by the liver are also not directly related to why Lasmiditan is not contraindicated in patients with CVD. While these factors may play a role in drug interactions and metabolism, they do not explain the safety of Lasmiditan in patients with CVD.